Cytotoxic Effect of Hep88 mAb: A Novel Monoclonal Antibody Against Hepatocellular Carcinoma

摘要: Fifteen novel monoclonal antibodies (mAbs) against S102, an establishedhepatocellular carcinoma cell line from a Thai patient, were tested at 50-500 μg/mlconcentration for proliferation inhibitory activity various types of commercialhuman cancer lines i.e., HepG2 (liver), Chago (lung), A375 (melanoma), Kato-III(gastric) and SW 620 (lymph node). To compare these effects, we alsoverified them normal liver line, Chang liver, as well two theestablished hepatocellular patients, S102 R12 the samemAbs concentration. The viability cells after exposure to 15 mAbs wasdetermined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) colorimetricmethods. result showed that, their IC50 concentration only 4 ofthem (Hep20: = 100 μg/ml, Hep44: 300 Hep88: μg/ml andHep94: 200 mAbs) illustrated thehepatocellular including HepG2, R12. Interestingly, Hep88mAb inhibited growth approximately 70 95%, respectively, 100μg/ml, whereas it gave tumoricidal effect same concentration.It had no on liver. Moreover, when compared with theeffect anti-oncogenic cytokine, interferon alfa-n1 (IFN) its concentration(IC50 1,000 U/ml), Hep88 mAb lesser cytotoxicity line.These results suggest that might play important role not in inhibitoryeffects but also lethal effects without disturbing normalcells. Accordingly, this antibody may be promising tool therapeutic era ofhepatocellular next decade.